Alzheimer's Disease News
-
Novartis AG plans to ramp up its research in Alzheimer’s disease, a potential $20 billion market lacking a major contender and littered with three high-profile drug failures in the past year alone.
-
A cheap regimen of vitamins in use for decades is seen by scientists as a way to delay the start of Alzheimer’s disease and dementia, a goal that prescription drugs have failed to achieve.
-
Standard physicals are, well, pretty standard. During a visit geared more toward detecting disease than preventing it, your doctor makes you cough and checks your numbers. If there’s an abnormality -- your blood pressure has spiked or your liver enzymes are elevated -- it’s your schedule that suffers as you’re shuttled between specialists.
-
Bristol-Myers Squibb Co., pouring resources into new immune system-based cancer drugs, said it also plans to expand development of treatments for congestive heart failure and fibrosis.
-
Evidence against Mathew Martoma, the former SAC Capital Advisors LP portfolio manager charged with insider trading, includes e-mails from SAC and third parties and trading records, federal prosecutors said.
-
About 1 in 8 Americans at least 60 years old reported confusion or memory loss in the preceding 12 months, according to health officials highlighting the need to be alert for early signs of dementia or Alzheimer’s disease.
-
Baxter International Inc.’s Gammagard failed to help patients with Alzheimer’s disease in a late-stage study, adding to a string of failures to develop a treatment for the most common form of dementia.
-
U.S. stocks rose, sending the Dow Jones Industrial Average to its first close above 15,000, on optimism over global central bank stimulus and better-than- estimated corporate earnings.
-
Elan Corp. considered buying New York investment firm Royalty Pharma last year, about six months before Royalty Pharma turned around with an acquisition proposal for Elan that’s now valued at about $5.7 billion.
-
Eli Lilly & Co. sought to revoke a patent held by a Johnson & Johnson unit, arguing at a London court it might delay availability of a potential treatment for Alzheimer’s.
|
|
Alzheimer's Disease Photos
Most Popular on Bloomberg
|
|
Alzheimer's Disease Videos
|
|
Rate this Page